Drugs / GX-188E
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01634503 | Nov 2012 → Feb 2014 | cervical intraepithelial neoplasia grade 2/3 | Genexine, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03444376 | Jun 2018 → Apr 2022 | cervical cancer | Genexine, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05280457 | Apr 2022 → Jan 2027 expected | head and neck squamous cell carcinoma | Yonsei University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02596243 | Aug 2015 → Mar 2018 | cervical intraepithelial neoplasia | Genexine, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT02139267 | Jul 2014 → Mar 2016 | cervical intraepithelial neoplasia | Genexine, Inc. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03206138 | May 2017 → Oct 2018 | cervical intraepithelial neoplasia grade 2/3 | Seoul St. Mary's Hospital | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05286060 Background | Mar 2022 → Oct 2026 expected | head and neck squamous cell carcinoma | Yonsei University | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GX-188E | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02139267 ↗ |
| Modality | Vaccine | “GX-188E, a DNA-based therapeutic vaccine” NCT01634503 ↗ |
| Route | Intramuscular | “intramuscular injection of GX-188E” NCT01634503 ↗ |